

AUG 09 2002

RECEIVED

Hundred and Ten Dollars (\$110.00) to cover the extension fee as required by 37 C.F.R. §1.17(a)(1) and 1.136(a). Because the date for responding to the Office Action with a one-month extension of time falls on a Saturday, e.g. June 22, 2002, this Amendment is nevertheless considered timely as it is being filed on the next succeeding day which is not a Saturday, Sunday, or Federal holiday (37 C.F.R. §1.7).

IN THE CLAIMS:

Cancel claim 27.

Replace claims 16, 22 and 26 with amended claims 16, 22 and 26.

16. (Twice amended) The pharmaceutical formulation according to any one of claims 1-10, further comprising a bile acid binder.

22. (Twice amended) The method according to claim 15, further comprising administering a therapeutically effective amount of a bile acid binder for the prophylactic or therapeutic treatment of a subject suffering from, or susceptible to, diarrhea during therapy comprising administration of the IBAT inhibitor compound.

26. (Amended) A method for the prophylaxis or therapeutic treatment of hypercholesterolemia comprising simultaneously, separately or sequentially administering therapeutically effective amounts of a pharmaceutical formulation according to any one of claims 1-10 and a bile acid binder to the patient in need thereof.

Add new claims 28-35 as follows:

28. (New) The pharmaceutical formulation according to claim 16, wherein the IBAT inhibitor and the bile acid binder are administered simultaneously, separately, or sequentially.

29. (New) A pharmaceutical formulation for the prophylactic or therapeutic treatment of hypercholesterolemia, comprising therapeutically effective amounts of an IBAT inhibitor

compound and a bile acid binder, wherein the formulation is formulated to release the bile acid binder in the colon.

30. (New) The pharmaceutical formulation according to claim 29, wherein the IBAT inhibitor compound is a low permeability drug as defined in the FDA Biopharmaceutical Classification System.

31. (New) The pharmaceutical formulation according to claim 29, wherein the bile acid binder is a resin.

32. (New) The pharmaceutical formulation according to claim 29, wherein the IBAT inhibitor compound and the bile acid binder are administered simultaneously, separately or sequentially.

33. (New) A pharmaceutical formulation for the prophylactic or therapeutic treatment of hypercholesterolemia, comprising therapeutically effective amounts of IBAT inhibitor compound and a bile acid binder, wherein the formulation is formulated to release the IBAT inhibitor compound in the ileum and the bile acid binder in the colon.

34. (New) A method for the prophylactic or therapeutic treatment of a subject suffering from, or susceptible to, hypercholesterolemia, comprising administering to the subject a therapeutically effective amount of the pharmaceutical formulation according to any one of claims 29-33.

35. (New) A method for the prophylactic or therapeutic treatment of a subject suffering from, or susceptible to, diarrhea during administration of an IBAT inhibitor compound, comprising administering to the subject a therapeutically effective amount of the pharmaceutical formulation according to any one of claims 29-33.